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httpcense.Abstract Introduction: Despite broad implementation of a bundled strategy aimed at preventing
ventilator-associated adverse events in many hospitals, the ability of the bundle to prevent VAP has
not been deﬁnitively established with high-quality studies.
Aim of the work: To implement VAP bundle as a performance improvement project in adult
ICU and follow up the compliance rate over the 12 month study period as well as the effectiveness
on surgical and medical subgroups.
Patients and method: VAP Bundle Program was implemented in adult ICU, data were collected
and analyzed for ventilated-associated pneumonia (VAP), and compared before and after interven-
tion. Our bundle components were head of bed elevation greater than 30, daily sedation break,
assessment for extubation, peptic ulcer prophylaxis and deep vein thrombosis prophylaxis.
Results: The results clearly show the difference between pre and post-intervention period and
lower VAP rate after application of VAP bundle. The total VAP bundle compliance rate steadily
increased during the period of implementation. We documented a signiﬁcant reduction of mean
ICU LOS (from 15.4 ± 5.2 to 10.8 ± 4.9 days) and duration of mechanical ventilation (from
12.8 ± 4.9 to 8.5 ± 4.3 days) for patients with VAP bundle compliance at the end of the study.
There was a signiﬁcant improvement in the outcome of surgical patients who were studied after
VAP bundle initiation reﬂecting a decreased mortality rate.
Conclusion: Our study highlights that adherence with the VAP-bundle approach in our ICU
decreases the incidence of VAP, more rapid ventilator weaning, fewer ICU days, and shorterl.com
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10 K.A.E. Mohamedhospitalizations and it has also a great impact on patient outcomes. Our study looked into surgical
sub-population as getting more beneﬁt by initiation of the VAP bundle in reducing the length of
stay. Thus it results in a decrease in the burden of the health care costs and the ICU resources.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B .V .Open access under CC BY-NC-ND license.Introduction
Ventilator-associated pneumonia (VAP) is an airway infection
that must have been developed more than 48 h after the patient
was intubated. It has been reported to occur in 9–27% of all
intubated patients [1]. The overall rate of ventilator-associated
pneumonia (VAP) was 13.6 per 1000 ventilator days according
to International Nosocomial Infection Control Consortium
(INICC) report data summary for 2003–2008 compared to
3.3 per 1000 ventilator-days in the US National Healthcare
Safety Network (NHSN; formerly the National Nosocomial
Infection Surveillance system (NNIS) [2,3]. Importance of this
issue reﬂects the high incidence and making VAP among the
most common infection in ICUs and the high cost of treatment
($11 000–$57 000) with a greater number of days in the inten-
sive care unit (ICU), longer duration of mechanical ventila-
tion, and higher mortality [4]. Awareness of the gap between
guideline dissemination and clinical practice has led to efforts
by individual hospitals and health care systems to institute
programs aimed at complying with VAP prevention guidelines
to reduce the burden of this nosocomial infection [5]. Reducing
mortality due to ventilator-associated pneumonia requires an
organized process that guarantees early recognition of pneu-
monia and consistent application of the best evidence based
practices [6]. The Ventilator Bundle is a series of interventions
developed by the Institute for Healthcare Improvement (IHI)
related to ventilator care that, when implemented together, will
achieve signiﬁcantly better outcomes than when implemented
individually [7,8]. The IHI ventilator bundle has been broadly
adopted by many hospitals as part of the effort to reduce VAP.
The use of VAP bundle has been reported to decrease the inci-
dence of VAP in the intensive care units (ICUs) in few studies
[8]. No large randomized study has demonstrated that reduc-
ing VAP using any VAP prevention strategy, including those
in the IHI bundle, is associated with improvements in clinical
outcomes. More recently a multidimensional strategy that in-
cluded a bundle of infection control interventions, education,
outcome surveillance, process surveillance, feedback on VAP
rates, and performance feedback on infection control practices
was associated with a signiﬁcant reduction in VAP rate in neo-
natal ICUs in developing countries [9].
The main objective of this study was to implement VAP
bundle as a performance improvement project in the critical
care unit for all mechanically ventilated patients aiming to de-
crease the VAP rates. Secondly to follow the compliance rate
over the 12 month study period and analyze the effectiveness
of the implementation of ventilator bundle on surgical and
medical subgroups.
Patients and method
This study was conducted in our adult medical ICU of Manial
Specialist Hospital in Cairo university. VAP Bundle Program
was implemented in September 2012 by our team and our studywas initiated through retrospective review of prospectively col-
lected data from infection control. Reports from ICU for the
period from September 2011 to August 2012 were reviewed.
All the adult medical and surgical patients who were intubated
and ventilated in our ICU from September 2012 to August 2013
were included in the study. The critical care nurses and the staff
were educated and made aware about the problem of VAP and
the use of ventilator bundle in helping to decrease this nosoco-
mial infection. Patients who were transferred to other hospital
or expired within 48 h of admission, and those who were diag-
nosed with pulmonary embolism or had gastrointestinal bleed-
ing prior to admission were excluded from this study.
Data were collected and analyzed for ventilated-associated
pneumonia (VAP) for the mentioned period of time and com-
pared before and after intervention. Patients were included if
they were mechanically ventilated for more than 48 h and were
at least 18 years of age. A day on mechanical ventilation was
deﬁned as any 24 h period in which the patient required any
mode of controlled or assisted ventilation, with the exception
of intermittent application of continuous positive airway pres-
sure for atelectasis prophylaxis. Assignment of patients to
nursing staff and clinicians was not controlled by the study
protocol, routine laboratory study including ABG was done.
Standard unit measures of general critical care were applied
to all patients, including the current practice of hand washing,
tracheal suction, and daily oral care. The medical manage-
ment, antibiotic therapy, and weaning from the ventilator were
left to the treating physician’s discretion. Our bundle compo-
nents are as follows:
(1) Head of bed elevation greater than 30.
(2) Daily sedation break.
(3) Daily assessment for extubation.
(4) Peptic ulcer prophylaxis.
(5) Deep vein thrombosis prophylaxis.
Compliance was assessed twice daily by the ICU team. Ven-
tilator associated pneumonia (VAP) was deﬁned as per the
Center of Disease Control (CDC) as a pneumonia that occurs
in a patient who was intubated and ventilated at the time of or
within 48 h before the onset of the event. Pneumonia was iden-
tiﬁed using a combination of radiological, clinical, and labora-
tory criteria. In our study VAP was clinically diagnosed based
on modiﬁed CDC criteria [10]. Presence of any two of the fol-
lowing was considered as diagnostic of VAP.
(1) Signiﬁcant heavy growth reported in the culture from
tracheal aspirates.
(2) Temp.: >38 c or < 35 c.
(3) Development of progressive new inﬁltrate on X-ray.
(4) Leukocytosis WBC >10 · 109/L or leucopenia WBC
<3 · 109/L.
(5) Ten leucocytes per HPF in gram stain of tracheal
aspirates.
Compliance with VAP bundle implementation and its effectiveness 11VAP rates were calculated based on occurrences per 1000
ventilator days and monitored on a monthly basis throughout
the project period.
Incidence of VAP was calculated in the medical and surgi-
cal sub-populations who were subjected to VAP bundle. The
outcome measures that were analyzed were mean length of
stay, mean duration of ventilation, and the incidence of gastro-
intestinal bleeding.
Teams conducted regular daily rounds on all ventilated pa-
tients and recorded compliance with the ﬁve elements of the
VAP bundle. The entire bundle was considered compliant only
if all 5 items were completed. A bundle was considered non-
compliant if any item was not performed, even if that item
was contraindicated. The only exception was contraindication
to deep vein thrombosis prophylaxis in patients with head in-
jury; the bundle was still considered compliant in this case. We
were very concerned about the delay of antibiotic therapy,
even for just a few hours, in this susceptible population. There-
fore, because survival is improved in the patients receiving
appropriate empirical antibiotics, guidelines recommend the
coverage of all potential pathogens responsible for an episode
of ventilator-associated pneumonia (VAP). Collection of bron-
chial specimen precedes the administration of empirical antibi-
otics [10]. The choice of antibiotics is based on the presence of
speciﬁc risk factors. After the responsible bacteria in samples
were identiﬁed, guidelines recommend reassessing the antibi-
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Figure 1 VAP bundle compliance rates and VAP rates in ICU
over the study period.
Table 1 Characteristics of patients included in the study before an
Before VAP bundle
Age(years) 61.8 ± 5.6
Male/female 69/36
LOS in ICU 15.4 ± 5.2
Duration of MV 12.8 ± 4.9
APACHE score 21.4 ± 4.2
upper GIT bleed 16%
Incidence of VAP (36) 34%
Re-intubation rate (27) 26%
Mortality (24) 23%
LOS in ICU: length of stay in ICU(days), Duration of MV: duration ofmean ± SD and qualitative data are given as number and per-
centage. Normal distribution of data was tested via Kolmogo-
rov–Smirnov test and by Fisher’s exact test for categorical
variables. All tests were two-sided, and p< 0.05 indicated a
statistical signiﬁcance.
Results
The total number of patients requiring mechanical ventilation
in the previous year of the VAP bundle initiation were 105 pa-
tients and the cumulative VAP incidence was 34%. On the
other hand we studied 98 ventilated patients subjected to
VAP bundle with cumulative VAP incidence 18%. The mean
age of patients who were studied after VAP bundle initiation
was insigniﬁcantly lower than those before VAP bundle and
there is no signiﬁcant difference in sex distribution in the cur-
rent studied population.
The data were analyzed and compared on monthly basis
based on 1000 ventilator days. The rate of VAP raised up to
26/1000 ventilator days during the period from September
2011 to August 2012 and declined by the end of July 2013 to
be as low as 11/1000 ventilator days. The results clearly show
the difference between pre and post-intervention period and
lower VAP rate after application of VAP bundle. This corre-
lated with a decrease in the annual VAP rate from 23 per
1000 ventilator days before VAP bundle down to 14 per
1000 ventilator days after VAP bundle initiation. Lower
VAP rate was prospectively recorded in July before the end
of the study (Fig. 1). Statistical process control chart that mon-
itored the implementation of VAP bundle on a monthly basis
has revealed an improvement in compliance rate in the ICU.
Compliance with all measures just after VAP bundle imple-
mentation was as low as 57%. A level as high as 90% of total
compliance rate was only achieved at the last 3 months of the
study. The total VAP bundle compliance rate steadily in-
creased from 63% to 84% during the period of implementa-
tion. We documented a reduction of mean ICU LOS (from
15.4 ± 5.2 to 10.8 ± 4.9 days) and duration of mechanical
ventilation (from 12.8 ± 4.9 to 8.5 ± 4.3 days) for patients
with VAP bundle compliance at the end of the study. How-
ever, there was no statistically signiﬁcant difference in
APACHE score. The reduction in the incidence of upper gas-
trointestinal bleeding was statistically signiﬁcant after VAP
implementation (Table 1).
Efforts on VAP prevention and outcome improvement
should focus on achieving higher compliance in DVTd after VAP bundle initiation.
After VAP bundle P-value
57.7 ± 4.6 0.08
67/31 0.6
10.8 ± 4.9 0.036
8.5 ± 4.3 0.038





mechanical ventilation, (n) %: number, percentage.
Table 2 VAP bundle compliance rates at 1st quarter and last quarter of the study.
1st quarter
Mean compliance, % (range)
4th quarter
Mean compliance, % (range)
P-value
HOB elevation 76 (71–82) 85 (77–93) 0.04
Sedation break 76 (71–80) 92 (91–94) 0.03
Assessment for extubation 92 (87–97) 93 (92–95) 0.1
PU prophylaxis 87 (84–91) 94 (93–96) 0.045
DVT prophylaxis 78 (73–84) 96 (95–98) 0.018
Total compliance 63 (57–69) 84 (72–90) 0.02
HOB elevation: head of bed elevation, PU prophylaxis: peptic ulcer prophylaxis DVT prophylaxis: deep vein thrombosis prophylaxis.
Table 3 Results of deep tracheal aspirate of the studied
patients.
Organism 1 (%) 11 (%)
Pseudomonas aeruginosa (33) 31 (24) 24
Klebsiella pneumoniae (31) 29 (26) 26
Acinetobacter baumannii (10) 9 (11) 11
Stenotrophomonas maltophilia (7) 7 (8) 8
MRSA (4) 4 (2) 2
Serratia marcescens (3) 3 (4) 4
Candida (5) 5 (9) 9
Others (12) 11 (16) 16
1: before VAP bundle initiation, 11: after VAP bundle initiation.
(n)%: number percentage, MRSA: Methicillin-Resistant S. aureus.
Table 5 ABG, serum electrolyte and lactate at the onset of
VAP.
pH 7.25 ± 0.02 7.33 ± 0.05 0. 07
PaO2 (mmHg) 50 ± 5.33 49.77 ± 6.8 0.09
PaCO2 (mmHg) 39.35 ± 4.26 38.65 ± 5.08 0. 1
HCO3 (meq/L) 19.35 ± 2.86 20.42 ± 3.36 0.08
SO2 (%) 79.40 ± 4.65 83.98 ± 6.08 0.07
Na (mEq/L) 135.3 ± 5.14 134.8 ± 4.72 0.5
K (mEq/L) 3.89 ± 0.59 3.73 ± 0.47 0.2
Lactate (mmol/L) 2.4 ± 0.72 2.2 ± 0.5 0.13
12 K.A.E. Mohamedprophylaxis and PU prophylaxis followed by sedation break
and the head of the bed at 30 or more (Table 2). Pseudomonas
aeruginosa being the most common organism was isolated
from deep tracheal aspirate followed by Klebseillae pneumoniae
and Acinetobacter baumannii in both periods whether before or
after VAP bundle (Table 3). There were no signiﬁcant difference
in hemodynamics, hemoglobin, leukocytic count, ABG and
electrolyte at the onset of VAP either before or after VAP bun-
dle initiation (Tables 4 and 5). On the other hand, focusing on
surgical subgroup after VAP initiation revealed that both the
age and length of stay were signiﬁcantly lower than the medical
subgroup. The mean duration of ventilation and re-intubation
rate were signiﬁcantly higher in the medical subgroup (Table 6).
The improvement in outcome of surgical patients who were
studied after VAP bundle initiation reﬂected in a signiﬁcant
decrease in the rate of GIT bleeding as well as the mortality rate
at the end of the study.
Discussion
VAP occurs in up to 15% of patients receiving mechanical
ventilation. Risk factors include tracheostomy, multipleTable 4 Hemodynamics, hemoglobin and leukocytic count at the o
Parameter 1
Pulse (beats/min) 105.1 ± 9.8
MBP (mmHg) 74.6 ± 11.0
Respiratory rate (breaths/minute) 25.2 ± 6.7
HB 9.6 ± 3.8
WBCs/mm3 14.72 ± 3.51
1: before VAP initiation, 11: after VAP initiation, MBP: mean arterial bcentral line insertions, reintubation, and the use of antacids
[11]. The hospital mortality rate of ventilator patients who de-
velop VAP may be as high as 46%, compared to 32% for ven-
tilator patients who do not develop VAP [12]. The IHI has
developed a ventilator bundle that incorporates several strate-
gies to prevent morbidity associated with the ventilator. Three
elements of this bundle target VAP while 2 elements address
prevention of stress ulcers and thromboembolic disease [8].
Despite broad implementation of a bundled strategy aimed at
preventing ventilator-associated adverse events in many hospi-
tals, the ability of the bundle to prevent VAP has not been
deﬁnitively established with high-quality studies [2]. Our study
demonstrates that if no VAP bundle is implemented, it is obvi-
ous that VAP rates will continue to remain high as it rose up to
26 per 1000 ventilator days before VAP bundle initiation. On
the other hand the lowest VAP rate was prospectively recorded
in July before the end of the study. Even though there was an
improvement in the process of bundle compliance rate in
ICU with some variation and the process became stable the tar-
get of total compliance rate of 95% was never reached. There-
fore, the process would have been considered acceptable as this
correlated with a decrease in the VAP rate in our ICU. The
highest compliance rate with DVT prophylaxis and PU pro-
phylaxis followed, by sedation break and lastly the head of
the bed at 30 or more was achieved by the end of the study.nset of VAP.
11 P-value
102.8 ± 7.1 0.7
71.2 ± 13.2 0.8
26.1 ± 5.5 0.6
10.4 ± 2.7 0.09
15.5 ± 2.29 0.07
lood pressure, HB: hemoglobin, WBCs: white blood cells.
Table 6 Difference between surgical and medically ventilated
patients after VAP bundle application.
Surgical patients Medical patients P-value
Age(years) 47.3 ± 6.2 65 ± 5.2 0.03
Male/female 23/16 34/25 0.2
LOS in ICU 6.6 ± 5.3 13.7 ± 4.6 0.0 2
Duration of MV 5.24 ± 6.6 11.9 ± 6.3 0.02
APACHE score 18.3 ± 4.6 21.2 ± 6.6 0.08
Upper GIT bleed (0) 0% (3) 5% 0.04
Incidence of VAP (4) 10% (14) 24% 0.038
Re-intubation rate (3) 8% (13) 22% 0.02
Mortality (3) 8% (12) 20% 0.0 32
(n) %: number, percentage, LOS: length of stay.
Compliance with VAP bundle implementation and its effectiveness 13After the end of the study the compliance, VAP rates, inten-
sive-care unit length of stay (ICU LOS) and duration of
mechanical ventilation were evaluated. Our study reported
that a 34% of ventilated patients in our ICU developed VAP
before initiation of VAP bundle. This reﬂects the major prob-
lem that faces us and the stimulus to start improvement in a
resource limited environment including lack of nursing staff,
individual variability. Most studies have reported a varied inci-
dence from 17% to 30%, depending upon the diagnostic crite-
ria of VAP [13,14]. The reported incidence of VAP was higher
in academic institutions [15]. The decrease in the mean length
of stay and mean duration of ventilation was statistically sig-
niﬁcant in our patients subjected to VAP bundle. However, an-
other study evaluating these components of the bundle
reported a 95% adherence with the bundle and an associated
reduction in VAP, but investigators acknowledged that the
reduction may have been related to a concurrent improvement
program that focused on care of the ventilated patient [16].
The decrease in the incidence of gastrointestinal bleeding was
statistically signiﬁcant during the period of implementation
of VAP bundle as this could be attributed to high compliance
to PU prophylaxis which was supported by Zaydfudim et al.
[17]. We tried to study separate subpopulations in the same
intensive care unit in the period of VAP implementation aim-
ing to address its effect on the patient subpopulation and help
to determine the factors which prevent the effectiveness of this
practice.
The higher rate of VAP in medical subgroup after the bun-
dle was implemented could be attributed to higher mean age of
this population as the age and other co-morbidities are inde-
pendent risk factors for the development of VAP in critically
ill patients [12]. Another factor that helps in decreasing the rate
of VAP in surgical subgroup was a lower re-intubation rate
which may be a reason for limiting aspiration pneumonia
and infection. Furthermore the pathogenesis of VAP com-
mences in most cases with the bacteria entering the trachea
during initial intubation, during subsequent re-intubations as
this was studied by Wahl et al. when they reviewed more than
one hundred surgery and trauma patients who underwent BAL
within 48 h of intubation. They found that 90% of specimens
had some growth and 58% had at least 104 colony forming
units/ml. Patients subsequently diagnosed with VAP often
grew the same organisms as they were present on the initial
BAL. On the basis of this, they proposed that many eventslabeled as VAP are present or incubating on admission and
hence are not preventable [18]. Two studies from India have
shown contrastingly high VAP rates of 32.5% and 20% in chil-
dren ventilated in Pediatric Intensive Care Units (PICU)
[19,20]. In a recently published study from a tertiary care cen-
ter in north India, the incidence of VAP was reported as 17.5%
[21].
Most of organisms responsible for VAP in the current study
are multiresistant and require a higher broad spectrum of anti-
biotics for more than 7 days for cure. Thus this results in long-
er length of stay and prolonged use of ventilator support than
that reported by Song et al. [22]. There is always a threat to the
other patients of getting this infection as a result of cross con-
tamination through the hands of the health care workers. Our
study showed that pseudomonas aeruginosa followed by kleb-
siella pneumoniae was the most common organism in the cul-
ture whether before or after VAP bundle application a matter
that could be again explained by lack of concentration in dif-
ferent infection control measures at the study. An important
observation from our study was that the rate of death in the
intensive care unit appeared lower in ventilated patients after
initiation of VAP bundle despite the fact that we did not study
the individual risk factors, however APACHE score which al-
lows an assessment of the severity of disease showed no signif-
icant difference before or after initiation of VAP bundle. It is
also possible that decreased rate of re-intubation was the rea-
son for the signiﬁcant decrease of mortality, through a number
of mechanisms such as cardiac ischemia, aspiration pneumoni-
tis, and complications of emergency intubation and infection
[23].
A fact that may have added more value to VAP bundle
application in our study is, in spite of infection control mea-
sures playing a role in VAP prevention, our study did not look
into the different infection control measures at the study hos-
pitals. Furthermore the general preventive measures of hand
hygiene and circuit care are not a part of this bundle. The
beneﬁts in terms of decreased length of stay and decreased
duration of ventilation were also reﬂected on the cost. The
limitations of our study are a small population studied and
hence a collaborative multi-center cohort study to be con-
ducted in many adult intensive-care units. Further individual
risk factors which predispose the patients to the development
of VAP have not been considered. In conclusion, our study
highlights that adherence with the VAP-bundle approach in
our ICU decreases the incidence of VAP, more rapid ventilator
weaning, fewer ICU days, and shorter hospitalizations and it
has also a great impact on patient outcomes. Our study looked
into surgical sub-population as getting more beneﬁt by initia-
tion of the VAP bundle in reducing the length of stay. Thus
it results in a decrease in the burden of the health care costs
and the ICU resources.References
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